Cambridge, United States
Ring Therapeutics, founded by Flagship Pioneering in 2017, is at the forefront of developing a new class of targeted medicines. With a clear mission to pioneer advanced pharmaceutical solutions, the company is positioned within the Biotechnology, Health Care, Health and Wellness, and Pharmaceutical industries. Based in the United States, Ring Therapeutics emphasizes privacy and ensures client data security by avoiding requests for personal information outside secure channels.
The company recently secured a substantial $86.50M in its Series C funding round on 01 March 2023. This latest investment saw participation from notable investors such as Flagship Pioneering, Invus, Partners Investment, T. Rowe Price, Alexandria Venture Investments, Altitude Life Sciences, CJ Investment, Kyowa Kirin Co., and UPMC Enterprises. These strategic partnerships highlight the robust confidence investors place in Ring Therapeutics’ innovative approach and potential for future growth.
